Healthcare and Medical

Nanoparticle Based Screening Is Fastest Growing Segment Fueling The Growth Of Lung Cancer Diagnostic And Screening Market

Gauri Cmi

Nanoparticle Based Screening Is Fastest Growing Segment Fueling The Growth Of Lung Cancer Diagnostic And Screening Market

Lung cancer diagnostic and screening products help to detect the presence of cancer in the lungs at an early stage. These include imaging tests that can detect lung abnormalities and biopsy procedures to analyze lung tissue samples. Early detection improves treatment effectiveness and survival rates of lung cancer patients.

The global Lung Cancer Diagnostic And Screening Market is estimated to be valued at US$ 2458.7 Mn in 2023 and is expected to exhibit a CAGR of 10.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Rising adoption of nanoparticles-based screening is driving the growth of the lung cancer diagnostic and screening market. Nanoparticles are being widely used to develop new approaches for lung cancer screening and diagnostics. For instance, gold nanoparticles are being utilized to develop tests to detect tumor-specific proteins and tumor DNA in blood or sputum samples. They enhance the sensitivity and specificity of screening and diagnostic tests. Researchers are also exploring the use of nanoparticles as carriers for targeted drug delivery to lung cancer sites post-detection. This reduces toxicity and enhances therapeutic efficacy.

Segment Analysis

The global lung cancer diagnostic and screening market is segmented on the basis of type, product, end user and region. Based on type, the market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The non-small cell lung cancer (NSCLC) segment dominates the market due to its higher prevalence rate. NSCLC accounts for around 85% of all lung cancer cases.

Key Takeaways

Market size

The Global Lung Cancer Diagnostic And Screening Market Size is expected to witness high growth, exhibiting CAGR of 10.1% over the forecast period, due to increasing prevalence of lung cancer worldwide. According to GLOBOCAN estimates, lung cancer burden has risen to 2.21 million new cases in 2020 from 1.80 million new cases in 2018.

Regional analysis

Regionally, North America dominates the lung cancer diagnostic and screening market and is expected to continue its dominance over the forecast period. This is attributed to increasing funding from public and private bodies for lung cancer research, rising awareness regarding early diagnosis and screening, and significant per capita healthcare spending in the region.

Key players

Key players operating in the lung cancer diagnostic and screening market are Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc. , F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. These players are focusing on developing innovative diagnostic and screening technologies to gain a competitive edge in the market.

Get More Insights On This Topic: https://www.pressreleasebulletin.com/lung-cancer-diagnostic-and-screening-market-size/

Gauri Cmi

Lung Cancer Diagnostic And Screening Market Overview 2024-2033 – Competitive Landscape and Strategies

2024-03-01

Learn More On The Lung Cancer Diagnostic And Screening Market:https://www. The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market going forward. Therefore, the rise in the prevalence of lung cancer is driving the growth of the lung cancer diagnostic and screening market. The lung cancer diagnostic and screening market report table of contents includes:1.

The Global Lung Cancer Diagnostic And Screening Market Growing Adoption Of Digital Biomarkers To Diagnose And Screen Lung Cancer

2023-12-28

The lung cancer diagnostic and screening market encompasses various tools and technologies that are used to detect lung cancer at an early stage. The global Lung Cancer Diagnostic And Screening Market is estimated to be valued at US$ 2243. The quantitative collection of digital biomarkers through smartphones and wearable devices expands access to lung cancer screening tests and improves patient outcomes. Segment Analysis The global Lung Cancer Diagnostic and Screening market is dominated by the cancer diagnostics segment. The global lung cancer diagnostic and screening market Market is estimated to be valued at US$ 2243.

Lung Cancer Diagnostic and Screening Market - Advancements and Growth Opportunities

2023-08-25

A) Market Overview: The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 1,931. The market for lung cancer diagnostic and screening products has witnessed significant advancements in recent years, with the aim of improving accuracy, efficiency, and early detection of lung cancer. B) Market Key Trends: One key trend shaping the lung cancer diagnostic and screening market is the integration of artificial intelligence (AI) and machine learning (ML) techniques. D) Key Takeaways: - The global Lung Cancer Diagnostic and Screening Market is expected to witness high growth, exhibiting a CAGR of 7. In conclusion, the lung cancer diagnostic and screening market is poised for substantial growth due to increasing awareness, technological advancements, and the urgent need for early detection and accurate diagnosis.

Lung Cancer Diagnostic And Screening Procedures First Steps In Diagnosing Lung Cancer

2024-03-14

Diagnostic Imaging TestsIf a patient experiences concerning lung cancer symptoms or is considered at high risk, their doctor will likely order imaging tests to examine the lungs more closely. - MRI (Magnetic Resonance Imaging) Scan - Used less commonly than CT scans for lung cancer, MRI uses magnetic fields and radio waves rather than radiation. Studies show CT screening can reduce lung cancer deaths. Biomarker blood tests and chest X-rays are not recommended for lung cancer screening due to inferior accuracy versus CT. Get more insights, On Lung Cancer Diagnostic and Screening

Lung Cancer Diagnostic and Screening Market is Estimated to Witness High Growth Owing to the Rising Cases of Lung Cancer

2024-02-16

The global lung cancer diagnostic and screening market is estimated to be valued at USD 2585. According to the American Cancer Society, lung cancer accounts for about 25% of all cancer deaths in the United States. Technological advancements in lung cancer screening and diagnostic technologies are further contributing towards early and more effective detection of lung cancer. SWOT Analysis Strength: The lung cancer diagnostic and screening market has seen significant advancements in diagnostic technologies over the past few years. Key Takeaways The global lung cancer diagnostic and screening market is expected to witness high growth over the forecast period of 2024 to 2031 supported by the increasing prevalence of lung cancer. The global lung cancer diagnostic and screening market is estimated to be valued at USD 2585.

Revolutionizing Lung Cancer Diagnosis and Screening Market: A Market Overview

2023-08-22

The market offers advanced products designed to diagnose lung cancer at an early stage, allowing for timely treatment and improved patient outcomes. Threat of New Substitutes: The threat of new substitutes in the market is relatively low, as lung cancer diagnosis and screening require specialized products and technologies. Competitive Rivalry: The Lung Cancer Diagnostic and Screening Market is highly competitive, with significant market players such as Abbott, Illumina, Thermo Fischer Scientific, and QIAGEN leading the market. 8% over the forecast period, driven by the increasing prevalence of lung cancer and the growing demand for early-stage diagnosis. In conclusion, the Lung Cancer Diagnostic and Screening Market is poised for significant growth, driven by technological advancements, increasing cases of lung cancer, and the need for accurate and timely diagnosis.

WHO TO FOLLOW